HIKAL
|
HIKAL Last 5 Year Cashflow Statement History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Profit Before Tax | ₹105 Cr | ₹219 Cr | ₹206 Cr | ₹142 Cr | ₹149 Cr |
Adjustment | ₹163 Cr | ₹126 Cr | ₹127 Cr | ₹136 Cr | ₹159 Cr |
Changes In working Capital | ₹76 Cr | ₹19 Cr | ₹-58 Cr | ₹46 Cr | ₹-90 Cr |
Cash Flow after changes in Working Capital | ₹344 Cr | ₹364 Cr | ₹276 Cr | ₹325 Cr | ₹218 Cr |
Cash Flow from Operating Activities | ₹315 Cr | ₹294 Cr | ₹229 Cr | ₹285 Cr | ₹186 Cr |
Cash Flow from Investing Activities | ₹-292 Cr | ₹-284 Cr | ₹-156 Cr | ₹-164 Cr | ₹-125 Cr |
Cash Flow from Financing Activities | ₹-7.68 Cr | ₹-5.56 Cr | ₹-97 Cr | ₹-101 Cr | ₹-55 Cr |
Net Cash Inflow / Outflow | ₹15 Cr | ₹3.80 Cr | ₹-24 Cr | ₹20 Cr | ₹5.59 Cr |
Opening Cash & Cash Equivalents | ₹11 Cr | ₹7.64 Cr | ₹32 Cr | ₹11 Cr | ₹5.82 Cr |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - | - | - |
Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - | - | - |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - | - |
Effect of Foreign Exchange Fluctuations | - | - | - | - | - |
Closing Cash & Cash Equivalent | ₹27 Cr | ₹11 Cr | ₹7.64 Cr | ₹32 Cr | ₹11 Cr |
Compare Cashflow Statement of peers of HIKAL
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
HIKAL | ₹3,778.5 Cr | -2.7% | 13.7% | 8.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹365,167.0 Cr | 2.6% | -4.7% | 54.7% | Stock Analytics | |
CIPLA | ₹113,645.0 Cr | 4.4% | -4.4% | 54.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹105,890.0 Cr | 5.8% | 17.7% | 24.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹104,987.0 Cr | 5.7% | 2.7% | 29.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹96,950.6 Cr | 0.4% | -5.4% | 82.7% | Stock Analytics |
HIKAL Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
HIKAL | -2.7% |
13.7% |
8.1% |
SENSEX | 1.4% |
2.5% |
24.3% |
You may also like the below Video Courses